|
ZNF25 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62458935193399E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
5.55220314168992E-11 |
| Normal-vs-Stage3 |
3.33066907387547E-16 |
| Normal-vs-Stage4 |
4.33486579964892E-12 |
| Stage1-vs-Stage2 |
9.978200E-01 |
| Stage1-vs-Stage3 |
2.963000E-01 |
| Stage1-vs-Stage4 |
6.359200E-01 |
| Stage2-vs-Stage3 |
4.717400E-01 |
| Stage2-vs-Stage4 |
6.864400E-01 |
| Stage3-vs-Stage4 |
7.599000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.60388999999039E-05 |
| Normal-vs-Asian |
3.81869980081717E-10 |
| Caucasian-vs-AfricanAmerican |
1.408590E-01 |
| Caucasian-vs-Asian |
2.929400E-01 |
| AfricanAmerican-vs-Asian |
5.184600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.07611705604904E-14 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
3.771000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62458935193399E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.69197988952874E-12 |
| Normal-vs-Age(81-100Yrs) |
2.227600E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.654000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.729800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.972400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.352600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.924800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.296600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.268100E-02 |
| Classical-VS-Follicular |
9.051800E-01 |
| Classical-VS-Other |
6.148400E-01 |
| Classical-VS-Normal |
5.77404790647051E-12 |
| Tall-VS-Follicular |
3.428200E-02 |
| Tall-VS-Other |
4.806800E-01 |
| Tall-VS-Normal |
3.20965476419133E-13 |
| Follicular-VS-Other |
6.826000E-01 |
| Follicular-VS-Normal |
4.37319958024318E-10 |
| Other-VS-Normal |
6.642500E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
5.02931030155196E-14 |
| N0-vs-N1 |
4.471200E-01 |
|
|
